ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study

Mélanie Deschasaux, Fabien Szabo de Edelenyi, Nathalie Druesne‐Pecollo, Younes Esseddik, Julien Allègre, Bernard Srour, Pilar Galán, Serge Herçberg, Gianluca Severi, Marie Zins, Emmanuel Wiernik, Fabrice Carrat, Pierre‐Yves Ancel, Nathalie Bajos, Marie-Aline Charles, Mathilde Touvier, Sofiane Kab, Adeline Renuy, Stéphane Le Got, Céline Ribet, Mireille Pellicer, Marcel Goldberg, Fanny Artaud, Pascale Gerbouin-Rérolle, Mélody Enguix, C Laplanche, Roselyn Gomes-Rimav, Lyan Hoang, Emmanuelle Correia, Alpha Amadou Barry, Nadège Senina, Valérie Benhammou, Anass Ritmi, Laetitia Marchand‐Martin, Cécile Zaros, Elodie Lordmi, Adriana Candea, Sophie de Visme, Thierry Siméon, Xavier Thierry, Bertrand Geay, Marie‐Noëlle Dufourg, Karen Milcent, Clovis Lusivika‐Nzinga, Grégory Pannetier, Nathanaël Lapidus, Isabelle Goderel, Céline Dorival, Jérôme Nicol, Olivier Robineau, Cindy J. Lai, Liza Belhadji, Hélène Espérou, Sandrine Couffin-Cadièrgues, Jean‐Marie Gagliolo, Hélène Blanché, Jean-Marc Sébaoun, Jean-Christophe Beaudoin, Laëtitia Gressin, Valérie Deldrève, Ouissam Ouili, Jean‐François Deleuze, Stéphane Priet, Paola Mariela Saba Villarroel, Toscane Fourié, Souand Mohamed Ali, Abdenour Amroun, Morgan Seston, Nazlı Ayhan, Boris Pastorino, Xavier de Lamballerie, Nazli AyhanScientific 2023 · DOI

Abstract

ABO blood type has been reported as a potential factor influencing SARS-CoV-2 infection, but so far mostly in studies that involved small samples, selected population and/or used PCR test results. In contrast our study aimed to assess the association between ABO blood types and SARS-CoV-2 infection using seroprevalence data (independent of whether or not individuals had symptoms or sought for testing) in a large population-based sample. Our study included 67,340 French participants to the SAPRIS-SERO multi-cohort project. Anti-SARS-CoV-2 antibodies were detected using ELISA (targeting the proteins spike (S) and nucleocapsid (NP)) and seroneutralisation (SN) tests on dried blood spots collected in May-November 2020. Non-O individuals (and especially types A and AB) were more likely to bear anti SARS-CoV-2 antibodies (ELISA-S, 2964 positive cases: OR<sub>non-Ovs.O</sub> = 1.09[1.01-1.17], OR<sub>Avs.O</sub> = 1.08[1.00-1.17]; ELISA-S/ELISA-NP/SN, 678 triple positive cases: OR<sub>non-Ovs.O</sub> = 1.19 [1.02-1.39], OR<sub>Avs.O</sub> = 1.19[1.01-1.41], OR<sub>ABvs.O</sub> = 1.43[1.01-2.03]). Hence, our results provided additional insights into the dynamic of SARS-CoV-2 infection, highlighting a higher susceptibility of infection for individuals of blood types A and AB and a lesser risk for blood type O.

Introduction

Early in the COVID-19 pandemic, several reports suggested that blood type might play a role in susceptibility to SARS-CoV-2. However, these early investigations were often limited by small sample sizes, focused on specific subgroups such as hospitalized patients, or relied exclusively on PCR test results.

PCR-based data is inherently biased as it primarily captures individuals who were symptomatic or had the motivation to seek testing, thereby excluding asymptomatic "silent" infections. To accurately determine how blood type affects susceptibility, seroprevalence data—detecting antibodies that indicate past infection regardless of clinical symptoms—is essential. This study addresses these limitations by analyzing a massive population-based sample in France.

Methods and Datasets

The researchers utilized the SAPRIS-SERO multi-cohort study, drawing data from 67,340 participants across three major French prospective cohorts: Constances, E3N-E4N, and NutriNet-Santé. Between May and November 2020—a period before the introduction of vaccines and the emergence of major variants—participants provided dried blood spots via self-sampling kits.

Table 1: Characteristics of the study population by SARS-CoV-2 serostatus (ELISA-S).

To ensure diagnostic robustness, the study employed three distinct assays:

  • ELISA-S: Targeting the spike (S) protein.
  • ELISA-NP: Targeting the nucleocapsid (NP) protein.
  • Seroneutralisation (SN): A functional assay to determine if antibodies could neutralize the virus.

The most reliable results were derived from "triple positive" cases—individuals testing positive on all three assays. Multi-adjusted logistic regression was used to control for potential confounders, including age, sex, region, and smoking status.

Key Results and Insights

The study found clear statistical evidence that non-O blood types are at a higher risk of infection compared to Type O.

Table 2: Association between ABO/RhD blood types and SARS-CoV-2 seropositivity across different testing protocols.

Key findings from the triple-positive analysis include:

  • Non-O vs. O: Non-O individuals had a 19% higher risk of infection (OR = 1.19 [1.02–1.39]).
  • Type A: Specifically, Type A individuals showed a 19% higher risk compared to Type O (OR = 1.19 [1.01–1.41]).
  • Type AB: This group exhibited the highest susceptibility, with a 43% higher risk (OR = 1.43 [1.01–2.03]).
  • Type B: While the odds ratio was slightly elevated, it did not reach statistical significance, potentially due to the lower prevalence of Type B in the French population.
  • Rh Factor: The Rhesus factor (positive or negative) did not show a significant overall association with infection risk.

These results support the "ABO incompatibility" hypothesis. Individuals with Type O blood naturally possess anti-A and anti-B antibodies, which may neutralize virus particles carrying A or B antigens (shed by non-O infected individuals) before an infection can be established. Conversely, Type AB individuals lack these antibodies, increasing their vulnerability. Additionally, the A-antigen itself may facilitate viral entry into host cells.

Discussion and Limitations

While this study provides robust evidence for the role of ABO blood types in SARS-CoV-2 susceptibility, several limitations exist. Seroprevalence studies may miss individuals whose antibody levels waned below detectable limits by the time of testing. Furthermore, the data reflects the "wild type" virus; it remains unclear if these dynamics persist with newer variants like Omicron.

Due to regulatory constraints in France, ethnic diversity data could not be collected, which is a known factor in blood type distribution. Finally, while Type O offers some relative protection, the authors emphasize that this is a collective rather than individual safeguard. Standard protective measures remain the primary defense for all individuals, regardless of blood type. Future research should investigate if these associations extend to long COVID or vaccine breakthrough cases.

Summary updated

Abstract

ABO blood type has been reported as a potential factor influencing SARS-CoV-2 infection, but so far mostly in studies that involved small samples, selected population and/or used PCR test results. In contrast our study aimed to assess the association between ABO blood types and SARS-CoV-2 infection using seroprevalence data (independent of whether or not individuals had symptoms or sought for testing) in a large population-based sample. Our study included 67,340 French participants to the SAPRIS-SERO multi-cohort project. Anti-SARS-CoV-2 antibodies were detected using ELISA (targeting the proteins spike (S) and nucleocapsid (NP)) and seroneutralisation (SN) tests on dried blood spots collected in May-November 2020. Non-O individuals (and especially types A and AB) were more likely to bear anti SARS-CoV-2 antibodies (ELISA-S, 2964 positive cases: OR<sub>non-Ovs.O</sub> = 1.09[1.01-1.17], OR<sub>Avs.O</sub> = 1.08[1.00-1.17]; ELISA-S/ELISA-NP/SN, 678 triple positive cases: OR<sub>non-Ovs.O</sub> = 1.19 [1.02-1.39], OR<sub>Avs.O</sub> = 1.19[1.01-1.41], OR<sub>ABvs.O</sub> = 1.43[1.01-2.03]). Hence, our results provided additional insights into the dynamic of SARS-CoV-2 infection, highlighting a higher susceptibility of infection for individuals of blood types A and AB and a lesser risk for blood type O.
BibTeX
@inproceedings{deschasaux2023abo,
  author = {Mélanie Deschasaux and Fabien Szabo de Edelenyi and Nathalie Druesne‐Pecollo and Younes Esseddik and Julien Allègre and Bernard Srour and Pilar Galán and Serge Herçberg and Gianluca Severi and Marie Zins and Emmanuel Wiernik and Fabrice Carrat and Pierre‐Yves Ancel and Nathalie Bajos and Marie-Aline Charles and Gianluca Severi and Mathilde Touvier and Marie Zins and Sofiane Kab and Adeline Renuy and Stéphane Le Got and Céline Ribet and Mireille Pellicer and Emmanuel Wiernik and Marcel Goldberg and Marie Zins and Fanny Artaud and Pascale Gerbouin-Rérolle and Mélody Enguix and C Laplanche and Roselyn Gomes-Rimav and Lyan Hoang and Emmanuelle Correia and Alpha Amadou Barry and Nadège Senina and Gianluca Severi and Fabien Szabo de Edelenyi and Julien Allègre and Nathalie Druesne‐Pecollo and Younes Esseddik and Serge Herçberg and Mathilde Touvier and Marie-Aline Charles and Pierre‐Yves Ancel and Valérie Benhammou and Anass Ritmi and Laetitia Marchand‐Martin and Cécile Zaros and Elodie Lordmi and Adriana Candea and Sophie de Visme and Thierry Siméon and Xavier Thierry and Bertrand Geay and Marie‐Noëlle Dufourg and Karen Milcent and Clovis Lusivika‐Nzinga and Grégory Pannetier and Nathanaël Lapidus and Isabelle Goderel and Céline Dorival and Jérôme Nicol and Olivier Robineau and Fabrice Carrat and Cindy J. Lai and Liza Belhadji and Hélène Espérou and Sandrine Couffin-Cadièrgues and Jean‐Marie Gagliolo and Hélène Blanché and Jean-Marc Sébaoun and Jean-Christophe Beaudoin and Laëtitia Gressin and Valérie Deldrève and Ouissam Ouili and Jean‐François Deleuze and Stéphane Priet and Paola Mariela Saba Villarroel and Toscane Fourié and Souand Mohamed Ali and Abdenour Amroun and Morgan Seston and Nazlı Ayhan and Boris Pastorino and Xavier de Lamballerie and Xavier de Lamballerie and Fabrice Carrat and Mathilde Touvier and Toscane Fourié and Souand Mohamed Ali and Abdenour Amroun and Morgan Seston and Nazli Ayhan and Boris Pastorino and Xavier de Lamballerie and Xavier de Lamballerie and Fabrice Carrat and Mathilde Touvier},
  title = {{ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study}},
  booktitle = {Scientific},
  year = {2023},
  doi = {10.1038/s41598-023-30714-9},
}
Figure